These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29750295)

  • 1. Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line.
    Ochiai K; Azakami D; Morimatsu M; Hirama H; Kawakami S; Nakagawa T; Michishita M; Egusa AS; Sasaki T; Watanabe M; Omi T
    Oncol Rep; 2018 Jul; 40(1):488-494. PubMed ID: 29750295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro.
    Ozbun MA; Jerry DJ; Kittrell FS; Medina D; Butel JS
    Cancer Res; 1993 Apr; 53(7):1646-52. PubMed ID: 8453637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
    Kamada R; Nomura T; Anderson CW; Sakaguchi K
    J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model.
    Murphy KL; Dennis AP; Rosen JM
    FASEB J; 2000 Nov; 14(14):2291-302. PubMed ID: 11053251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors.
    Lee CH; Kweon OK
    J Vet Sci; 2002 Dec; 3(4):321-5. PubMed ID: 12819382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.
    Fischer NW; Prodeus A; Malkin D; Gariépy J
    Cell Cycle; 2016 Dec; 15(23):3210-3219. PubMed ID: 27754743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.
    Rollenhagen C; Chène P
    Int J Cancer; 1998 Oct; 78(3):372-6. PubMed ID: 9766574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an adenoviral vector that expresses the canine p53 gene on cell growth of canine osteosarcoma and mammary adenocarcinoma cell lines.
    Yazawa M; Setoguchi A; Hong SH; Uyama R; Nakagawa T; Kanaya N; Nishimura R; Sasaki N; Masuda K; Ohno K; Tsujimoto H
    Am J Vet Res; 2003 Jul; 64(7):880-8. PubMed ID: 12856773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic alterations in eight mammary tumors and tumor-suppressor gene p53 mutation in one mammary tumor from dogs.
    Mayr B; Dressler A; Reifinger M; Feil C
    Am J Vet Res; 1998 Jan; 59(1):69-78. PubMed ID: 9442248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.
    Lee CH; Kim WH; Lim JH; Kang MS; Kim DY; Kweon OK
    J Vet Sci; 2004 Mar; 5(1):63-9. PubMed ID: 15028887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
    Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
    Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
    Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
    Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
    Gencel-Augusto J; Lozano G
    Genes Dev; 2020 Sep; 34(17-18):1128-1146. PubMed ID: 32873579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tetramerization in p53 function.
    Chène P
    Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imbalance between apoptosis and cell proliferation during early stages of mammary gland carcinogenesis in ACI rats.
    Kutanzi KR; Koturbash I; Bronson RT; Pogribny IP; Kovalchuk O
    Mutat Res; 2010 Dec; 694(1-2):1-6. PubMed ID: 20659487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
    Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
    Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
    Xu X; Qiao W; Linke SP; Cao L; Li WM; Furth PA; Harris CC; Deng CX
    Nat Genet; 2001 Jul; 28(3):266-71. PubMed ID: 11431698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.